A clinical trial compared the efficacy and safety of metformin sustained-release (SR) tablets by Dulening and the original metformin tablets by Glucophage in treating type 2 diabetes mellitus (T2DM) with 886 patients involved.
Both groups showed similar reductions in glycated hemoglobin (HbA1c) levels, fasting blood glucose (FBG), and weight loss after 16 weeks of treatment.
However, the Dulening group experienced significantly fewer adverse drug reactions (ADRs), particularly gastrointestinal issues, indicating it may be a safer option.